Cargando…
Adjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node
OBJECTIVE: Whether to administer adjuvant treatment is a matter of great debate for oral cavity cancer harboring a single positive node without extranodal extension and positive margin (defined as low/intermediate risk pN1(new) in this study). METHODS: A total of 243 low/intermediate risk pN1(new) p...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665423/ https://www.ncbi.nlm.nih.gov/pubmed/34938872 http://dx.doi.org/10.1002/lio2.679 |
_version_ | 1784614006392094720 |
---|---|
author | Chen, Wan‐Yu Fang, Ku‐Hao Wang, Chun‐Wei Liao, Chun‐Ta Yen, Tzu‐Chen Fang, Taun‐Jen Lai, Shih‐Fan Liang, Hsiang‐Kuang Huang, Bing‐Shen |
author_facet | Chen, Wan‐Yu Fang, Ku‐Hao Wang, Chun‐Wei Liao, Chun‐Ta Yen, Tzu‐Chen Fang, Taun‐Jen Lai, Shih‐Fan Liang, Hsiang‐Kuang Huang, Bing‐Shen |
author_sort | Chen, Wan‐Yu |
collection | PubMed |
description | OBJECTIVE: Whether to administer adjuvant treatment is a matter of great debate for oral cavity cancer harboring a single positive node without extranodal extension and positive margin (defined as low/intermediate risk pN1(new) in this study). METHODS: A total of 243 low/intermediate risk pN1(new) patients with oral cavity cancer who received curative surgery were included. Overall survival (OS), local recurrence‐free survival (LRFS), regional recurrence‐free survival (RRFS), and distant metastasis‐free survival (DMFS) were compared between patients receiving adjuvant treatment and observation alone. RESULTS: For patients receiving adjuvant therapy vs observation, the differences in outcomes were not statistically significant in terms of 5‐year OS, LRFS, RRFS, and DMFS. For subgroup analysis, in low/intermediate pN1(new) patients with one or more minor risk factors, adjuvant therapy was not significantly associated with OS, LRFS, RRFS, or DMFS in pN1(new) patients. CONCLUSION: For low/intermediate risk pN1(new) patients with oral cavity cancer, adjuvant therapy might be omitted. LEVEL OF EVIDENCE: 4. |
format | Online Article Text |
id | pubmed-8665423 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86654232021-12-21 Adjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node Chen, Wan‐Yu Fang, Ku‐Hao Wang, Chun‐Wei Liao, Chun‐Ta Yen, Tzu‐Chen Fang, Taun‐Jen Lai, Shih‐Fan Liang, Hsiang‐Kuang Huang, Bing‐Shen Laryngoscope Investig Otolaryngol Head and Neck, and Tumor Biology OBJECTIVE: Whether to administer adjuvant treatment is a matter of great debate for oral cavity cancer harboring a single positive node without extranodal extension and positive margin (defined as low/intermediate risk pN1(new) in this study). METHODS: A total of 243 low/intermediate risk pN1(new) patients with oral cavity cancer who received curative surgery were included. Overall survival (OS), local recurrence‐free survival (LRFS), regional recurrence‐free survival (RRFS), and distant metastasis‐free survival (DMFS) were compared between patients receiving adjuvant treatment and observation alone. RESULTS: For patients receiving adjuvant therapy vs observation, the differences in outcomes were not statistically significant in terms of 5‐year OS, LRFS, RRFS, and DMFS. For subgroup analysis, in low/intermediate pN1(new) patients with one or more minor risk factors, adjuvant therapy was not significantly associated with OS, LRFS, RRFS, or DMFS in pN1(new) patients. CONCLUSION: For low/intermediate risk pN1(new) patients with oral cavity cancer, adjuvant therapy might be omitted. LEVEL OF EVIDENCE: 4. John Wiley & Sons, Inc. 2021-10-19 /pmc/articles/PMC8665423/ /pubmed/34938872 http://dx.doi.org/10.1002/lio2.679 Text en © 2021 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Head and Neck, and Tumor Biology Chen, Wan‐Yu Fang, Ku‐Hao Wang, Chun‐Wei Liao, Chun‐Ta Yen, Tzu‐Chen Fang, Taun‐Jen Lai, Shih‐Fan Liang, Hsiang‐Kuang Huang, Bing‐Shen Adjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node |
title | Adjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node |
title_full | Adjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node |
title_fullStr | Adjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node |
title_full_unstemmed | Adjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node |
title_short | Adjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node |
title_sort | adjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node |
topic | Head and Neck, and Tumor Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665423/ https://www.ncbi.nlm.nih.gov/pubmed/34938872 http://dx.doi.org/10.1002/lio2.679 |
work_keys_str_mv | AT chenwanyu adjuvanttherapymaybeomittedfororalcavitycancerwithonlyonepositivelymphnode AT fangkuhao adjuvanttherapymaybeomittedfororalcavitycancerwithonlyonepositivelymphnode AT wangchunwei adjuvanttherapymaybeomittedfororalcavitycancerwithonlyonepositivelymphnode AT liaochunta adjuvanttherapymaybeomittedfororalcavitycancerwithonlyonepositivelymphnode AT yentzuchen adjuvanttherapymaybeomittedfororalcavitycancerwithonlyonepositivelymphnode AT fangtaunjen adjuvanttherapymaybeomittedfororalcavitycancerwithonlyonepositivelymphnode AT laishihfan adjuvanttherapymaybeomittedfororalcavitycancerwithonlyonepositivelymphnode AT lianghsiangkuang adjuvanttherapymaybeomittedfororalcavitycancerwithonlyonepositivelymphnode AT huangbingshen adjuvanttherapymaybeomittedfororalcavitycancerwithonlyonepositivelymphnode |